The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
about
The extended statistical analysis of toxicity tests using standardised effect sizes (SESs): a comparison of nine published papersAdvances in Nuclear Magnetic Resonance for Drug Discovery.The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin.A chiral liquid chromatography method for the simultaneous determination of oxcarbazepine, eslicarbazepine, R-licarbazepine and other new chemical derivatives BIA 2-024, BIA 2-059 and BIA 2-265, in mouse plasma and brain.Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.Reverse-translational biomarker validation of Abnormal Repetitive Behaviors in mice: an illustration of the 4P's modeling approachToward a molecular understanding of protein solubility: increased negative surface charge correlates with increased solubilityFormulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant.Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion in the study of anemoside B4, a novel antiviral agent candidate, in rats.Strategies to improve oral drug bioavailability.The road map to oral bioavailability: an industrial perspective.Caco-2 cell permeability assays to measure drug absorption.Preclinical formulations for discovery and toxicology: physicochemical challenges.Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Applications of genetically modified tools to safety assessment in drug developmentPharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa.Predictive toxicology approaches for small molecule oncology drugs.Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates.Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development.High-content screening for the discovery of pharmacological compounds: advantages, challenges and potential benefits of recent technological developments.In silico tools used for compound selection during target-based drug discovery and development.Application of a PEG precipitation method for solubility screening: a tool for developing high protein concentration formulations.Interpretation of the dissolution of insoluble peptide sequences based on the acid-base properties of the solvent.An evaluation of the relative roles of the unstirred water layer and receptor sink in limiting the in-vitro intestinal permeability of drug compounds of varying lipophilicity.A comparative study of support vector machine, artificial neural network and bayesian classifier for mutagenicity prediction.The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.Metabolism of CJ-036878, N-(3-phenethoxybenzyl)-4-hydroxybenzamide, in liver microsomes and recombinant cytochrome P450 enzymes: metabolite identification by LC-UV/MS(n) and (1)H-NMR.In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS.Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.Cholinium-based ionic liquids with pharmaceutically active anions
P2860
Q28545208-78C00DA9-B264-41E2-A11B-F855288D557AQ30387229-DB3F9BF7-EC6E-48AC-AC22-4D239196D57EQ30670381-198C2955-E486-40CC-A10B-66B40150A025Q33895725-2361E235-C822-45C0-B92F-EE05B276D0BFQ33968508-70657BF1-A91A-4CFF-B2DB-E34190C0119DQ34510604-1B5F4288-8647-4788-A755-1572F1415863Q34708790-9CBD490C-04EA-4B7A-9254-B85E44AAC3F9Q35895112-7829C72B-58A0-4969-9504-B61BCB71DE97Q35915885-AD33833E-8B66-4642-98CD-EB0FB537E882Q36221394-F23A23D7-2CDD-4B6F-9DE3-EA6BDBF5C3D1Q36316751-CB3C553D-C225-4308-8CF2-860922DA1C8AQ36543116-B254B083-42E9-4C68-AE23-1F2E24B9FD17Q36572562-694F50A1-3D49-48E8-BAF3-112433E90430Q36609758-79434A1F-E3B3-4254-A729-0A7EBA15C0C5Q36662875-DEE433CA-6878-4465-BC22-7C3826008284Q37326539-4DF2D961-E47B-4A7B-B635-7222124351C9Q37361955-91017A50-1668-430E-870C-C30CA6FED88CQ37407693-1D04DB3F-BC0C-4954-8E3C-4693C7230F60Q37675456-D24A8996-BE30-4E45-9280-85EAE02442A6Q37694755-B7CA39FB-91EA-4241-A7E8-6B16D8DE23B4Q37766391-93EFF765-228D-49A7-803C-39ED10E1A008Q38028519-D12D4DFE-CF36-4A85-98D5-50936523BCD3Q38465124-130319C7-F333-4191-AFDE-9152898B5482Q41785937-853D41BC-7EB1-49BC-A15D-3663E2879F19Q43043676-27C10E86-3A4F-4721-BB04-DDB2BD74C706Q43453290-72E4B2C0-EE3D-485F-A955-0499C586FAB1Q44219505-A2F7266E-6C5A-40A6-B844-A08682388045Q46595813-3EDAE072-E691-4A5B-9E43-9CDAD78DF840Q46886062-9D4F9942-A276-41AF-A26B-9A66473F48CCQ51910623-77F1D25C-597F-4E03-8994-4F4254A41AE4Q54346229-EFF1FFDC-6274-4F50-AF98-EE7CC0CE423DQ58802577-6890A30E-BE03-49EC-8F78-847DF1C0379B
P2860
The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The new pre-preclinical paradi ...... and late phase drug discovery.
@ast
The new pre-preclinical paradi ...... and late phase drug discovery.
@en
The new pre-preclinical paradi ...... and late phase drug discovery.
@nl
type
label
The new pre-preclinical paradi ...... and late phase drug discovery.
@ast
The new pre-preclinical paradi ...... and late phase drug discovery.
@en
The new pre-preclinical paradi ...... and late phase drug discovery.
@nl
prefLabel
The new pre-preclinical paradi ...... and late phase drug discovery.
@ast
The new pre-preclinical paradi ...... and late phase drug discovery.
@en
The new pre-preclinical paradi ...... and late phase drug discovery.
@nl
P2093
P356
P1476
The new pre-preclinical paradi ...... and late phase drug discovery.
@en
P2093
P304
P356
10.2174/1568026013394949
P577
2001-11-01T00:00:00Z